Drugs / Retigabine IR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01336621 | Feb 2011 → Dec 2016 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retigabine IR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01336621 ↗ |